- Long-term follow-up of children with high-risk neuroblastoma: the ENSG5 trial experienceLucas Moreno
Children and Young People s Unit, The Royal Marsden NHS Foundation Trust The Institute of Cancer Research, Sutton, Surrey, United Kingdom
Pediatr Blood Cancer 60:1135-40. 2013..The aim of this study was to identify the nature and severity of late complications of metastatic neuroblastoma survivors included in the ENSG5 clinical trial...
- How can attrition rates be reduced in cancer drug discovery?Lucas Moreno
Paediatric Drug Development, Children and Young People s Unit, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton SM2 5PT, UK 44 0 208 661 3678 44 0 208 661 3617
Expert Opin Drug Discov 8:363-8. 2013..Finally, there is a need for increased collaboration to combine the unique strengths between industry, academia and regulators to ensure that the needs of all stakeholders are met...
- Preclinical drug development for childhood cancerLucas Moreno
The Royal Marsden NHS Foundation Trust, Children and Young People s Unit, Sutton, Surrey, UK
Expert Opin Drug Discov 6:49-64. 2011..More effective drugs are needed to treat poor prognosis paediatric malignancies. Development of anticancer agents for childhood cancers faces several unique challenges compared with their adult counterparts...